EU MDR Labeling & IFU Compliance Consulting

Medical device labeling requirements depend on the market, device type, and risk class, but generally include the device name, manufacturer details, intended purpose, warnings, storage conditions, traceability information, and any mandatory symbols or identifiers. Under EU MDR, labeling must also align with Annex I Section 23, include applicable UDI elements, and remain consistent with the technical documentation and IFU.

Yes, IFUs are legally required for many medical devices when safe use cannot be ensured without them. Under EU MDR, the need for an IFU depends on the device and whether users can operate it safely based on labeling alone. When required, the IFU must contain specific mandatory content, appropriate warnings, and language versions suitable for each intended European market.

EU MDR requires labeling and IFUs to meet Article 10(11) and Annex I Section 23 requirements. That includes mandatory device and manufacturer information, safety information, intended purpose, residual risk communication, applicable symbols, UDI details, and language compliance for each target market. The content must also align with the device's technical documentation, risk management file, and clinical claims.

Most devices placed on the EU market under EU MDR are subject to UDI requirements, though implementation details vary by device class and regulatory timelines. The label must include the appropriate UDI carrier and related information where required. A compliance review helps confirm whether your device falls within the applicable scope and whether the label presentation meets current EU MDR expectations.

Sometimes partially, but not without careful review. EU MDR, FDA, and TGA labeling frameworks overlap in some areas yet differ in mandatory statements, symbol expectations, language obligations, and market-specific formatting rules. Reusing global labeling without jurisdiction-specific assessment often creates compliance gaps. A structured review helps preserve consistency while adapting content to each market's legal requirements.

An EU MDR IFU review typically checks mandatory content against Annex I Section 23, verifies intended use consistency, evaluates warnings and precautions, confirms symbol usage, and assesses alignment with risk management, clinical evidence, and technical documentation. Reviewers also identify translation gaps, missing statements, and unsupported claims so the final IFU is clearer, more defensible, and better prepared for Notified Body scrutiny.

Common gaps include missing mandatory content, inconsistent intended use statements, unsupported marketing claims, incomplete warnings, incorrect or unexplained symbols, absent UDI elements, and poor alignment between labels, IFUs, and technical documentation. Translation readiness is another frequent issue. These problems can trigger Notified Body questions, delay CE marking timelines, or create post-market compliance exposure if not corrected early.

Labeling and IFU compliance should be reviewed before Notified Body submission, before market expansion into new EU countries, after significant design or intended use changes, and whenever regulatory requirements are updated. Early review is especially valuable because labeling issues often affect GSPR mapping, risk communication, and technical documentation consistency. Catching gaps before submission reduces rework and helps protect timelines.